REVB
Revelation Biosciences, Inc.NASDAQHealthcare$1.16-7.20%ClosedMarket Cap: $1.7M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.81
P/S
0.00
EV/EBITDA
0.91
DCF Value
$1.51
FCF Yield
-481.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-134.2%
ROA
-77.0%
ROIC
-94.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-2.6M | $-2.5M | $-1.65 | — |
| FY 2025 | $0.00 | -Infinity% | $-9.1M | $-8.9M | $-23.95 | — |
| Q3 2025 | $0.00 | -Infinity% | $-1.9M | $-1.9M | $-1.77 | — |
| Q2 2025 | $0.00 | -Infinity% | $-2.5M | $-2.4M | $-7.01 | — |
| Q1 2025 | $0.00 | -Infinity% | $-2.1M | $-2.1M | $-2.11 | — |
| Q4 2024 | $27.0K | 50.0% | $-1.8M | $-1.7M | $-4.98 | — |
| FY 2024 | $0.00 | -Infinity% | $-8.0M | $-15.0M | $-87.68 | — |
| Q3 2024 | $0.00 | -Infinity% | $-1.8M | $-2.2M | $-13.38 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.5M | $-8.4M | $-82.09 | — |
| Q1 2024 | $0.00 | -Infinity% | $-1.9M | $-2.7M | $-39.37 | — |
| Q4 2023 | $37.6K | 50.0% | $-2.3M | $-2.2M | $-133.24 | — |
| FY 2023 | $0.00 | -Infinity% | $-8.7M | $-120.3K | $-8.41 | — |